|
|
|
| Efficacy of Citicoline Sodium Capsules Combined with Edaravone Dexborneol and Butylphthalide in the Treatment of Elderly Patients with Acute Progressive Cerebral Infarction |
| SHA Fei |
| Department of Neurology, Guannan County First People's Hospital, Lianyungang Jiangsu 222500 |
|
|
|
|
Abstract 【Objective】 To investigate the efficacy of citicoline sodium capsules combined with edaravone dexborneol and butylphthalide in the treatment of elderly patients with acute progressive cerebral infarction (APCI). 【Methods】 A total of 122 elderly patients with APCI were randomly divided into a control group (treated with edaravone dexborneol and butylphthalide) and an observation group (treated with citicoline sodium capsules in addition to the regimen used in the control group), with 61 cases in each group. Clinical efficacy, activities of daily living before and after treatment [Barthel Index (BI) score], neurological function [National Institutes of Health Stroke Scale (NIHSS) score], hemodynamic parameters, vascular endothelial function [vascular endothelial growth factor (VEGF) and nitric oxide (NO)], and adverse reactions were compared between the two groups. 【Results】 After treatment, the total effective rate in the observation group was higher than that in the control group (P<0.05). The BI score in the observation group was higher, while the NIHSS score was lower than those in the control group (P<0.05). The mean blood flow velocity of the middle cerebral artery and cerebral perfusion pressure in the observation group were higher than those in the control group, while the resistance index was lower (all P<0.05). The levels of VEGF and NO in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Citicoline sodium capsules combined with edaravone dexborneol and butylphthalide in the treatment of elderly patients with APCI can improve clinical efficacy and activities of daily living, alleviate neurological impairment, enhance vascular endothelial function, and improve cerebral blood supply.
|
|
Received: 14 October 2025
|
|
|
|
|
|
[1] SHARMA D, SMITH M. The intensive care management of acute ischaemic stroke[J].Curr Opin Crit Care,2022, 28(2):157-165.
[2] RAJENDRAN R, KUNNIL A, RADHAKRISHNAN A, et al. Current trends and future perspectives for enhanced drug delivery to central nervous system in treatment of stroke[J].Ther Deliv,2023, 14(1):61-85.
[3] 曾宁, 李才正, 夏勇, 等. 胞磷胆碱钠片联合电脑认知功能系统训练对脑卒中认知功能障碍患者血清NPAS4、γ-GGT及ICAM-1的影响[J].临床和实验医学杂志, 2022, 21(22):2359-2363.
[4] 刘前, 邓倩, 周静, 等. 依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J].中国老年学杂志, 2023, 43(2):276-279.
[5] WANG A X,JIA B X, ZHANG X L, et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial[J].JAMA Neurol,2023, 80(8):851-859.
[6] 赵玲娟,刘岩,文力.《中国急性缺血性卒中诊治指南2023》治疗策略解析[J].临床药物治疗杂志,2024,22(11):1-6.
[7] 杨娟,赵晓晖,李锦师,等. 丁苯酞注射液治疗不同严重程度的大脑中动脉脑梗死患者的疗效[J].昆明医科大学学报,2019,40(4):101-106.
[8] 李青,杨晓慧,吴婧,等. 替罗非班与传统双联抗血小板治疗在急性进展性脑梗死患者中的临床疗效及安全性评价[J].药品评价,2025,22(7):821-825.
[9] 刘勇,李宝栋,张良洪,等. 替罗非班联合奥拉西坦治疗急性进展性脑梗死患者的临床评价[J].中国药物应用与监测,2025,22(8):1330-1334.
[10] 陈丽君, 赵文杰, 陈浩, 等. 胞磷胆碱钠胶囊联合尤瑞克林治疗急性脑梗死的效果及对血清Hcy、CRP水平的影响[J].中国现代医学杂志, 2023, 33(16):55-59.
[11] 刘海燕,王丹,陈晗. 丁苯酞氯化钠注射液联合依达拉奉右莰醇注射用浓溶液对急性脑梗死患者神经功能和脑血流的影响[J].中国医药,2026,21(1):57-61.
[12] 么蕊,王玲,王鑫,等. 依达拉奉右莰醇治疗急性脑梗死对神经功能、脑血流灌注及炎性状态的影响[J].中华保健医学杂志,2025,27(2):201-205.
[13] 龙海红,唐军,闫俊峰. 刺血醒脑法对急性脑梗死患者脑血流动力学及血清VEGF、bFGF的影响[J].中国中医急症,2024,33(5):831-834.
[14] 邓燕萍,林枫,赖立文. 阿替普酶联合尤瑞克林治疗老年急性脑梗死患者的临床效果及对血清Fibulin-5、NO、S100B表达的影响[J].中国医学创新,2023,20(24):40-44. |
|
|
|
2026, Vol. 43 
